A mathematical model for comparison of bolus injection, continuous infusion, and liposomal delivery of doxorubicin to tumor cells

Neoplasia

Volumn 2, Issue 4, 2000, Pages 325-338

  El Kareh, A W ^a   Secomb, T W ^a  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

Continuous infusion; Doxorubicin; Drug delivery; Liposome; Tumor

Indexed keywords

DOXORUBICIN; LIPOSOME;

ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BLOOD TOXICITY; BLOOD VESSEL PERMEABILITY; BOLUS INJECTION; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CARDIOTOXICITY; CELL LEVEL; CELL MEMBRANE TRANSPORT; CONTINUOUS INFUSION; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DIFFUSION; DRUG EXTRAVASATION; DRUG HALF LIFE; DRUG UPTAKE; HEAT SENSITIVITY; HYPERTHERMIA; MATHEMATICAL MODEL; MUCOSA INFLAMMATION; PREDICTION; PRIORITY JOURNAL;

EID: 0033822142     PISSN: 15228002     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.neo.7900096     Document Type: Article

References (68)

1. Pharmacokinetic-toxicodynamic relationships of adriamycin in rat: Prediction of butylated hydroxyanisole-mediated reduction in anthracycline cardiotoxicity
2. Dose optimization of anthracyclines
3. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion
4. A risk-benefit assessment of anthracycline antibiotics in antineoplastic therapy
5. Decreased cardiac toxicity of doxorubicin administered by continuous intravenous infusion in combination chemotherapy for metastatic breast carcinoma
6. Anthracyclines and anthracenediones
7. A prospective randomized trial of adjuvant chemotherapy with bolus versus continuous infusion of doxorubicin in patients with high-grade extremity soft tissue sarcoma and an analysis of prognostic factors
8. Cellular pharmacokinetics of doxorubicin in patients with chronic lymphocytic leukemia: Comparison of bolus administration and continuous infusion
9. Liposomes: Opportunities in drug delivery
10. A comparative study on the antitumor effect, cardiotoxicity and nephrotoxicity of doxorubicin given as a bolus, continuous infusion or entrapped in liposomes in the Lou/M Wsl rat
11. Antibody-targeted delivery of doxorubicin entrapped in sterically stabilized liposomes can eradicate lung cancer in mice
12. Therapy of human ovarian carcinoma xenografts using doxorubicin encapsulated in sterically stabilized liposomes
13. Polyethylene glycol-liposomal doxorubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the management of AIDS-related Kaposi's sarcoma
14. Phase II study of liposomal doxorubicin in refractory ovarian cancer: Antitumor activity and toxicity modification by liposomal encapsulation
15. Toxicity of doxorubicin entrapped within long-circulating liposomes
16. Thermosensitive liposomes: Extravasation and release of contents in tumor microvascular networks
17. Enhanced therapeutic effect against liver W256 carcinosarcoma with temperature-sensitive liposomal adriamycin administered into the hepatic artery
18. Simultaneous measurement of liposome extravasation and content release in tumors
19. Hyperthermia-mediated targeted delivery of thermosensitive liposome-encapsulated melphalan in murine tumors
20. Intracellular uptake, retention and cytotoxic effect of adriamycin combined with hyperthermia in vitro
21. Enhancement of doxorubicin-induced cytotoxicity by hyperthermia in Ehrlich ascites cells
22. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin
23. Pharmacokinetics of adriamycin in patients with breast cancer: Correlation between pharmacokinetic parameters and clinical short-term response
24. Flow cytometry studies of intracellular adriamycin in single cells in vitro
25. Doxorubicin resistance in P388 leukemia - Evidence for reduced drug influx
26. The influence of tumor cell density on cellular accumulation of doxorubicin or cisplatin in vitro
27. Laser flow cytometric studies on the intracellular fluorescence of anthracyclines
28. Comparative intracellular uptake of adriamycin and 4'-deoxydoxorubicin by non-small cell lung tumor cells in culture and its relationship to cell survival
29. Preliminary pharmacokinetic model for adriamycin
30. Theoretical models for drug delivery to solid tumors
31. Prediction of adriamycin disposition in cancer patients using a physiologic, pharmacokinetic model
32. Intra-arterial infusion of anticancer drugs: Theoretic aspects of drug delivery and review of responses
33. Optimal control analysis of a cancer chemotherapy problem
34. General applications of optimal control theory in cancer chemotherapy
35. Development of a pharmacokinetic/pharmacodynamic (PK/PD)-simulation system for doxorubicin in long circulating liposomes in mice using peritoneal P388
36. Optimization of antitumor effect of liposomally encapsulated doxorubicin based on simulations by pharmacokinetic/pharmacodynamic modeling
37. Cellular pharmacokinetics of doxorubicin in cultured mouse sarcoma cells originating from autochthonous tumors
38. Anthracycline subcellular distribution in human leukemic cells by microspectrofluorometry: Factors contributing to drug-induced cell death and reversal of multidrug resistance
39. Infusional anthracyclines: Is slower better? If so, why?
40. Doxorubicin and doxorubicinol pharmacokinetics and tissue concentrations following bolus injection and continuous infusion of doxorubicin in the rabbit
41. Transport of fluid and macromolecules in tumors: I. Role of interstitial pressure and convection
42. Radiologic assessment of intranodal vascularity in head and neck squamous cell carcinoma. Correlation with histologic vascular density
43. Vascularization of malignant testicular tumors
44. Stepen' vaskuliarizatsii opukholi kak prognosticheskii faktor effektivnosti neoad'iuvantnoi polikhimioterapii pri rake molochnoi zhelezy
45. Multiple cycles of high-dose doxorubicin and cyclophosphamide with G-CSF mobilized peripheral blood progenitor cell support in patients with metastatic breast cancer
46. High-dose doxorubicin, etoposide, and cyclophosphamide with stem cell reinfusion in patients with metastatic or high-risk primary breast cancer
47. Microscopic localization of sterically stabilized liposomes in colon carcinoma-bearing mice
48. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes
49. Accumulation of liposomal lipid and encapsulated doxorubicin in murine Lewis lung carcinoma: The lack of beneficial effects by coating liposomes with poly (ethylene glycol)
50. Influence of vesicle size, lipid composition, and drug-to-lipid ratio on the biological activity of liposomal doxorubicin in mice
51. Role of drug release and liposome-mediated drug delivery in governing the therapeutic activity of liposomal mitoxantrone used to treat human A431 and LS180 solid tumors
52. The role of tumor-associated macrophages in the delivery of liposomal doxorubicin to solid murine fibrosarcoma tumors
53. Safety aspects of pegylated liposomal doxorubicin in patients with cancer
54. Clinical efficacy and prospects for use of pegylated liposomal doxorubicin in the treatment of ovarian and breast cancers
55. Direct measurement of doxorubicin concentration in the intact, living single cancer cell during hyperthermia
56. Interaction between adriamycin cytotoxicity and hyperthermia: Growth-phase-dependent thermal sensitization
57. Reduced adriamycin concentration in rat mammary tumors treated previously with hyperthermia
58. Modulation of adriamycin transport by hyperthermia as measured by fluorescence-activated cell sorting
59. Tissue perfusion inhomogeneity during early tumor growth in rats
60. Diffusion and convection in normal and neoplastic tissues
61. Transport of molecules in the tumor interstitium: A review
62. Measurement of material extravasation in microvascular networks using fluorescence video-microscopy